Study of DF9001 in Patients With Advanced Solid Tumors
Ontology highlight
ABSTRACT: DF9001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express epidermal growth factor receptor (EGFR). A combination therapy cohort will be opened for enrollment, DF9001 + nivolumab. The second phase will include a dose expansion using the best dose selected from the first phase of the study. Multiple cohorts will be opened with eligible patients having selected solid tumors.
DISEASE(S): Colorectal Cancer,Non-small Cell Lung Cancer,Solid Tumor, Adult,Neoplasms
PROVIDER: 2752778 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA